C-8XTIRejenevie Therapeutics
immune restoration, stem cell therapy, parabiosis
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-8XTI
C-8XTIC-8XTIimmune restoration, stem cell therapy, parabiosis
0-100 chain-logic scale · 15 dimensions · scored on public evidence
%PDF-1.7 %���� 56 0 obj > stream H���yTSw�oɞ����c [���5la� QIBH�ADED���2�mtFOE�.�c��}���0��8��8G�Ng��� ��9�w���߽����'����0 �֠�J��b� 2y�.-;!���K�Z� ���^�i�"L��0���-�� @8(��r�;q��7�L��y��&�Q��q�4�j���|�9�� �V��)g�B�0�i�W��8#�8wթ��8_�٥ʨQ����Q�j@�&�A)/��g�>'K���t�;\�� ӥ$պF�ZUn��� �(4T�%)뫔�0C&�����Z��i���8��bx��E���B �;�����P���ӓ̹�A� om?�W= �x������-�����[���0� ���}��y)7ta�����>j���T�7���@���tܛ�`q�2��ʀ��&���6�Z�L�Ą? �_ ��yxg)˔z���çL�U���*�u�Sk�Se�O4?�c����.�� ��R� ߁��-��2�5������ ��S�>ӣV����d�`r��n~��Y�&�+`��;�A4�� ���A9�=�-� t�
Houston-based Hines has broken... - Houston Business Journal Facebook Log In Houston Business Journal's Post Houston Business Journal Verified account October 5, 2021 · Shared with Public Houston-based Hines has broken ground on a 53-acre development that promises to put Houston on the map as a life sciences hub on par with San Francisco, San Diego and the famed Life Sciences Corridor in Boston. bizjournals.com Hines breaks ground on 53-acre life sciences district near TMC All reactions: 45 1 comment 6 shares Like Comment Most relevant Anna Baker Phillip Baker 4y
Steven J Greco - Montgomery, TX, Cornell University, Rutgers University, Rutgers Graduate School of Biomedical Sciences | about.me Get started for free Get your page Features Pricing Log In Home Features Pricing Steven J Greco Founder and Chief Operating Officer in Montgomery, TX Visit my website Steven J. Greco, PhD, is a distinguished leader in regenerative medicine and the Founder and Chief Operating Officer of PranaX Corporation, a cutting-edge biomedical research company based in Houston, TX. With a strong academic foundation in biological sciences from Cornell University and a PhD in Ste … ons to regenerative and translational medicine. His dedication to expanding the application of stem cells and regenerative therapies has positioned him as a key figure in the field. In addition to his research, Greco is passionate about educating others in regenerative medicine. As the founder of the Stem Cell Education Society, he has worked to raise awareness about stem cell applications and has provided valuable knowledge to students, researchers, and industry professional
List of 13 Cell Therapy Startups in Houston, United States & Market Trends (May 2026) - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubat … o Capital and 10 more March Biosciences Series A 2793 Nov 09, 2023 Cancer Focus Fund March Biosciences Series A 8852 Sep 01, 2023 - Cellvie Seed 7351 Feb 06, 2023 Taiho Ventures and 1 more See a more detailed list of funding rounds Top Investors in Cell Therapy in Houston Blackstone is the top investor in Cell Therapy companies in Houston based on number of companies invested. Here are some top investors in Cell Therapy companies in Houston : Investor Location Top Portfolio C … p Portfolio Companies Blackstone New York City ( United States ) - Cancer Focus Fund Houston ( United States ) March Biosciences Black Beret Life Sciences Houston ( United States ) Rejenevie Sixth Street San Francisco ( United States ) - Colton Capital Partners Houston ( United States ) Bellicum See a more detailed list of investors M&A activity in Cell Therapy sector in Houston In the year 2021, till July 2021, 2 acquisitions happened in Cell Therapy sector in Houston. H … ya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) Business Wire • Jan 05, 2026 • Coya Therapeutics • Coya Therapeutics Aims for ALS Treg Approval Based on Phase II Trial Clinical Trials Arena • Nov 20, 2025 • Coya Therapeutics • March Bio’s MB‑105 gains FDA RMAT for CD5+ T‑cell lymphoma Pharmaceutical Technology • Nov 12, 2025 • March Biosciences • FDA approves Coya Thera … y companies in Houston by number of investments are Blackstone and Cancer Focus Fund . How many exits have occurred in Cell Therapy companies in Houston? Cell Therapy sector in Houston has seen 2 acquisitions and 4 IPOs . Unlock complete sector data Sign Up for Free Related Links Overview of Cell Therapy Sector Cell Therapy Sector in United State
Our Platform – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu Our Platform At Houston Healthspan, our scientific platform drives development and growth with a suite of commercial and investigational technologies that include stem cell isolation devices and consumables, regenerative medicine therapies and healing amplification solutions. Through the rigorous implementation of protocols and acquisition of clinical data, we can accelerate development
%PDF-1.4 %���� 1 0 obj > endobj 4 0 obj >stream 2026-06-27T02:50:18-07:00 2020-08-02T14:48:07-07:00 2026-06-27T02:50:18-07:00 Appligent AppendPDF Pro 5.5 uuid:46212eb3-af03-11b2-0a00-782dad000000 uuid:6438439c-1dd2-11b2-0a00-380098e2e4ff application/pdf 8146374 Administrator Acrobat Distiller 8.1.0 (Windows) AppendPDF Pro 5.5 Linux Kernel 2.6 64bit Oct 2 2014 Library 10.1.0 endstream endobj 2 0 obj > endobj 3 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 12 0 obj > endobj 13 0 obj > endobj 14 0 obj > endobj 15 0 obj > endobj 16 0 obj > endobj 17 0 obj > endobj 71 0 obj >/ProcSet[/PDF/Text/I
Anne S. Bruce | Connectd Cookies Policy We use essential cookies to make our site work. With your consent, we may also use non-essential cookies to improve user experience and analyse website traffic. By clicking 'Accept', you agree to our website's cookie use as described in our Cookies Policy and Google's Privacy Policy. Accept Decline I'm an Expert Fractional Portfolio Find out how to build a fractional portfolio career Fractional Executive Find out how to become a Fractional Executive Board Advisor Find out how to become a Startup Board Advisor Independent Director Find out how to bec … our community Build your fractional and advisory career with growing startups. Apply today I'm a Startup Startup Services Hire fractional and advisory leaders Board Advisory Advisory Services Independent Director Independent Director Services Fractional HR Chief Human Resources Officer Fractional CMO Chief Marketing Officer Fractional CFO Chief Financial Officer Fractional COO Chief Operating Officer Fractional CTO Chief Technology Officer Fractional CIO Chief Informati … r for the latest news and updates straight to your inbox. Email Address * Submit Startups Startups Fractional Build a fractional portfolio career Become a Startup Board Advisor Independent Director Company About Careers Partnerships Referrals Knowledge Hub Blog Press Events Stories Startups Fractional Reviews Website Terms Acceptable Use Policy Cookie Policy Privacy Policy Terms & Conditions (Startups) Terms & Conditions (Fractionals) Instagram LinkedIn Site by
Glossary of Terms | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu GLOSSARY OF TERMS Allogeneic Cells or tissues derived from a donor. Autologous A patient’s own cells or tissue. Bone marrow In adults, bone marrow is primarily found inside the hip and breast bones and serves as part of the body’s hematopoietic and immune systems. Bone marrow houses a number of adult stem and pro … sion The administration of fluid and medication via intravenous or subcutaneous application. The Rejenevie™ immune restoration therapy utilizes an intravenous infusion to deliver a patient back their own restored immune cells. Leukapheresis The procedure in which white blood cells are separated from a sample of blood. MicroRNAs A small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals and some viruses, that functions in RNA silencing and post-
Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu News Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application August 21, 2019 / in News / by Lee Ann Crain New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing syste … hat an initial group of patients was successfully treated in the first clinical application of its Icellator® X technology at the Okyanos Center for Regenerative Medicine in Freeport, Bahamas. The new fully enclosed and automated system generated a higher yield of stem cells from adipose (fat) tissue than had been previously possible. The patients received stem cell therapy at the Okyanos clinic for conditions such as Parkinson’s disease, osteoarthritis, fibromyalgia and rheu … -09-12 00:31:17 Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application Archives September 2019 August 2019 May 2019 April 2019 August 2017 © 2026 · Houston Healthspan Innovation Group · All rights reserved. Privacy Policy | Terms of Use Rejenevie™ Therapeutics Announces Start of Phase Ib Immune Restoration Treatment... Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine... Scroll to top
%PDF-1.4 %���� 101 0 obj > endobj 98 0 obj >stream application/pdf SCTM20140132 1..9 2014-12-29T09:19:23+05:30 Arbortext Advanced Print Publisher 9.1.510/W Unicode 2015-01-05T12:59:18-08:00 2015-01-05T12:59:18-08:00 Acrobat Distiller 10.1.8 (Windows) uuid:3525eb7a-39ba-439f-9837-16a47e204dec uuid:78fb6ded-1dd2-11b2-0a00-11f6d81e9bff endstream endobj 95 0 obj > endobj 97 0 obj > endobj 196 0 obj > endobj 197 0 obj > endobj 36 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text]/Properties >>>/Rotate 0/Thumb 91 0 R/Type/Page>> endobj 43 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text]/Properties >>>/Rotat … ���� endstream endobj 70 0 obj > endobj 72 0 obj > endobj 71 0 obj >stream application/postscript Web Adobe Illustrator CS5 2013-08-23T18:56:16+05:30 2013-08-23T18:56:16+05:30 2013-08-23T18:56:16+05:30 256 8 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8 … AAF2C9375239E1 2013-08-23T18:56:16+05:30 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator Web 1 True False 800.000000 884.955566 Pixels Black Default Swatch Group 0 White CMYK PROCESS 0.003099 0.003099 0.003099 0.003099 Black CMYK PROCESS 77.740097 67.855299 58.373398 94.311398 R … xA;P/mjFXehL/y0SfdH/wA0Yq70Jf8Alok+6P8A5oxV3oS/8tEn3R/80Yq70Jf+WiT7o/8AmjFX/9k= application/postscript xmp.did:7718FB570E66E311AA3BA825AB736A28 xmp.iid:7718FB570E66E311AA3BA825AB736A28 uuid:1cbc7e7f-1dd2-11b2-0a00-9909271dc500 xmp.iid:7618FB570E66E311AA3BA825AB736A28 xmp.did:7618FB570E66E311AA3BA825AB736A28 uuid:1cbc7e7f-1dd2-11b2-0a00-9909271dc500 saved xmp.iid:3CBE5EEBC909E3119221DABF43F25059 2013-08-21T04:24:07+05:30 Adobe Illustrator CS5 / saved xmp.iid:76BF0A81EB09E31192 … 21DABF43F25059 2013-08-21T04:24:43+05:30 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:7618FB570E66E311AA3BA825AB736A28 2013-12-16T11:39:07+05:30 Adobe Illustrator CS5 / saved xmp.iid:7718FB570E66E311AA3BA8
Steven J. Greco, PhD – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu OUR TEAM Steven J. Greco, Ph.D. Chief Science Officer Dr. Steven Greco is the Chief Science Officer for Houston Healthspan and serves as Director of Research for Rejenevie Therapeutics. Formally trained as a stem cell biologist, over the past 14 years Dr. Greco has contributed to original research publications within the fields of regenerative and translational medicine. He is sk
Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu IN THE NEWS Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial May 29, 2019 / in News / by Lee Ann Crain Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-
Dr. W.E. “Ed” Bosarge Jr. Introduces Waun Ki Hong Award Recipient at the American Association of Cancer Research’s Annual Meeting – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu News Dr. W.E. “Ed” Bosarge Jr. Introduces Waun Ki Hong Award Recipient at the American Association of Cancer Research’s Annual Meeting April 1, 2019 / in News / by Lee Ann Crain ATLANTA (April 1, 2019) – W.E. “Ed” Bosarge Jr., PhD gave remarks Monday, April 1 st , at the A … eeting in Atlanta. He introduced this year’s recipient of the AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research , Dr. Andrew T. Chan. Bosarge endows this $10,000 award given annually to an outstanding cancer researcher under the age of 51 who has conducted highly meritorious translational and clinical cancer research. “We recognize your career, your work and the work of your team as the third recipient of the AACR Ki Hong award for being a leader driving … ntion and his 2007 landmark article in the New England Journal of Medicine. The award was established in 2017 in recognition of Waun Ki Hong, MD, FAACR, for his extraordinary contributions toward advancing cancer research, cancer care, and cancer prevention. Dr. Bosarge noted the poignance of this year’s award after Hong’s unexpected passing on January 2. “One role that brought him special joy was as a mentor to the many young scientists whose careers he nurtured.” He closed … Dr. Borsage was honored by the AACR in 2017 with a distinguished public service award . “We are honored to acknowledge Dr. Bosarge’s outstanding contributions to cancer research,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “Without his extraordinary support, we would not have been able to establish the AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research in perpetuity. These precious funds will help the AACR to recognize the work … 00:36:17 2019-09-12 00:50:39 Dr. W.E. “Ed” Bosarge Jr. Introduces Waun Ki Hong Award Recipient at the American Association of Cancer Research’s Annual Meeting Archives September 2019 August 2019 May 2019 April 2019 August 2017 © 2026 · Houston Healthspan Innovation Group · All rights reserved. Privacy Policy | Terms of Use TG & Human Life C
In the News | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu IN THE NEWS Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial May 29, 2019 / in News / by Lee Ann Crain Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases HOUSTON, May 29, 2019 — Rejenevie™ Therapeutics announced the
Rejenevie™ Therapeutics Announces Start of Phase Ib Immune Restoration Treatment Clinical Trial – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu News Rejenevie™ Therapeutics Announces Start of Phase Ib Immune Restoration Treatment Clinical Trial May 29, 2019 / in News / by Lee Ann Crain Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases HOUSTON, May 29, 2019 — Rejenevie™ Therapeutics announc … Privacy Policy | Terms of Use Dr. W.E. “Ed” Bosarge Jr. Introduces Waun Ki Hong Award Recipient at the... Tissue Genesis’ Icellator® X Delivers Results in First Clinical Applicat... Scroll to top
Lee Ann Crain, Author at Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu Author Archive for: [email protected] About Lee Ann Crain This author has yet to write their bio. Meanwhile lets just say that we are proud Lee Ann Crain contributed a whooping 1 entries. Entries by Lee Ann Crain Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial
About - Steven J Greco Steven J Greco Home About Blog Portfolio Resources Contact About Home / About About Steven J Greco Steven J. Greco, PhD, of Pinehurst, TX, is a leading figure in the field of regenerative medicine. As the Founder and Chief Operating Officer of PranaX Corporation, a Houston-based biomedical research and applications company, he has demonstrated his expertise in life sciences. His study of biological science at Cornell University, along with his doctoral work in biomedical science with a concentration in stem cell biology at Rutgers, has paved the way for his impressive su
Research Overview | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu RESEARCH OVERVIEW Our Research At Rejenevie™, we spent five years developing a sophisticated animal model to test our immune restoration therapy. Because the mouse genome is close in similarity to the human genome, and because it’s far easier to manipulate and change, there are many components of mouse biology th … btaining regulatory approval to treat patients in the Bahamas. We submitted our application in early 2017 to the Bahamian National Stem Cell Ethics Committee. Within one year, Rejenevie™ received approval to treat our first patient. To reach that point, we created a GMP (Good Manufacturing Practices) laboratory at our clinic, Okyanos Center for Regenerative Medicine, located in Freeport. Our first patient was treated on December 15, 2017, and we completed our Phase 1 trial of
Privacy Policy | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu PRIVACY POLICY Privacy Policy Effective Date: May 17, 2019 This Privacy Policy is incorporated by reference into the Rejenevie™ Terms of Use . The term “Rejenevie.com,” “we,” and “us” includes Advanced ReGen Medical Technologies, LLC, a Delaware limited liability company, doing business as Rejenevie™ and as Rejenevi … rmation, through your communications with our customer-support team or when you submit an information request by email or by using the Site. We may also collect the Personal Information, including health-related information, you provide when you attend events or respond to promotions. Cookies, Automatic Data Collection, and Related Technologies. The Site collects and stores information that is automatically generated as you use it, including your preferences and anonymous usa
Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu News Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development September 24, 2019 / in News / by Lee Ann Crain Houston-based accelerator to provide platform for growth to early stage life sciences and biotech companies HOUSTON, Sept. 24, 2019 /PRNewsw
Publications | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu PUBLICATIONS Preclinical Studies TITLE : “Heterochronic parabiosis for the study of the effects of aging on stem cells and their niches” SOURCE : Conboy IM, Rando TA. Heterochronic parabiosis for the study of the effects of aging on stem cells and their niches. Cell Cycle. 2012 Jun 15;11(12):2260-7. SUMMARY : Aging is
Raven.config('https://[email protected]/147999').install(); Houston millionaire starts biotech accelerator for companies focusing on regenerative medicine - InnovationMap X Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innovation Awards Promoted Advertise Subscribe INNOVATIONMAP EMAILS ARE AWESOME Sign up now About Us Advertise Submit a Story Terms of Use Privacy Policy Startups Tech Health Energy Impact Money Lifestyle Space Sports Featured Innovators Guest Columns Houston Voices Houston Innova
Product Pipeline | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu PRODUCT PIPELINE Product Pipeline Clinical Development – The Bahamas Our lead product, AR-100, is an autologous mobilized peripheral blood cell therapy utilizing the Rejenevie™ proprietary immune restoration technology. This therapy is currently in Phase II studies at The Okyanos Center for Regenerative Medicine,
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Home | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu Revolutionizing the way we treat age-related diseases Revolutionizing the way we treat age-related diseases If aging were a disease, it would affect 100% of the human population. As we age our immune system function weakens, while systemic inflammation rises. We become more susceptible to age-related and inflammatory diseases
Ed Bosarge – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu Executive Team Ed Bosarge CEO & Founder Dr. Bosarge is a world-renowned pioneer in the application of advanced mathematics to the fields of finance, medicine, and energy. Over the course of a remarkable career that has so far spanned more than six decades, he has developed innovative yet practical solutions to an exceptionally varied array of scientific and financial problems, while a
Study Scavenger Clinical Trial Recruitment Platform Archives - Page 244 of 379 - Clinical Trial Recruitment Find a Study Now Welcome to the future of clinical research recruitment Receive The Newest Study Notifications Email Text Select Page Volunteers / Patients To receive emails To receive text messages FAQs Blog Opt-Out HIPAA Privacy Policy Research Site Staff Register Login Forgot password Pricing Terms and Conditions HIPAA Digital marketing Contact Us Pharmaceutical Sponsors/ CROs Register Login Forgot password Multi-Site Pricing Terms and Conditions Multi-Site Digital marketing Contact u
%PDF-1.5 %���� 50 0 obj 20465 endobj 49 0 obj > stream ����ExifII*��Duckyd��ohttp://ns.adobe.com/xap/1.0/ ��&Adobed� �-�=O���������� 0!1"#@A2$34%!"1AQ2# 0aqBRb$�r�3���CsT%�45 !1AQa"2 0qB����R#���b��r���3CScs�@�$��!1AQaq 0���������� ��)�e\�φ5>�\� �Ey�Z{�^Si7�Y�����ͭ�H��۔�̅K�qf�� (�I- �K.Ӭ��\�Uj(��57����������Z�
Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Pho … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
This week, the Greater... - Greater Houston Partnership Facebook Log In Greater Houston Partnership's Post Greater Houston Partnership Verified account 1d · Shared with Public This week, the Greater Houston Partnership and our regional partners had the opportunity to connect with hundreds of global businesses at BIO International 2026! Home to the world's largest medical complex, a growing innovation ecosystem, and access to research and talent, Houston is where life sciences companies can start, scale and succeed. Thank you to our partners BioHouston, CenterPoint Energy , Partnershi
Our Clinic at Okyanos | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu OUR CLINIC AT OKYANOS Due to Hurricane Dorian, Okaynos has suspended operations for the foreseeable future. The clinic staff is still responding to patient inquiries and will return emails and phone calls as soon as possible. Our Clinic at Okyanos Okyanos is a regenerative medicine center of excellence locate
Aging Companies (for profits) - Google Sheets Die Datei kann in Ihrem Browser nicht geöffnet werden, weil JavaScript nicht aktiviert ist. Aktivieren Sie JavaScript und laden Sie die Seite noch einmal. Diese Browserversion wird nicht mehr unterstützt. Installieren Sie bitte einen unterstützten Browser. Aging Companies (for profits) Tab Extern Freigeben Anmelden Datei Bearbeiten Ansicht Einfügen Format Daten Tools Erweiterungen Hilfe Bedienungshilfen Fehlerbehebung Nicht gespeicherte Änderungen in Drive &n … NA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas FDA approved Tx proteostasis (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension humans 82 ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 siRNA pharma Yvonne Greenstreet, Kevin Fitzgerald Boston yes ALNY $38,902 2100 2442 2002 >$100M Onpattro, Amvuttra, Leqvio science presentations 2025-02-02 2024-08-15 *Borderline: Broad pr
Houston Healthspan Innovation Group | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Houston Healthspan Innovation Group Houston Healthspan Innovation Group is a Houston-based life-sciences accelerator that provides lab facilities, multidisciplinary expertise, and commercialization support to early-stage companies focused on regenerative medicine and immune-restoration therapies. The organization offers laboratory space (including cleanrooms and cGMP cell culture workstations), access to technical and regulatory expertise, a … #x27; point-of-care automated cell isolation delivers results in first clinical application Announcement describing a first clinical application of an automated, fully enclosed cell isolation system that produced higher yields of stem cells from adipose tissue. Start of Phase Ib immune restoration clinical trial Announcement regarding the commencement of a Phase Ib clinical trial for an immune restoration therapy targeting age-related immune decline. Similar organizations Bro
TS-143 - Drug Targets, Indications, Patents - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 TS-143 Last update 08 May 2025 Overview R&D Status Clinical Result Translational Medicine Deal Core Patent Clinical Trial Approval Regulation Overview Basic Info Drug Type Small molecule drug Synonyms Target HIF-PHs Action inhibitors Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) Therapeutic Areas Hemic and Lymphatic Diseases Active Indication Anemia Inactive Indication Acute posthaemorrhagic anaemia Chronic Kidney Dis … n made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid
Worldwide Anti-aging Therapeutics Industry to 2040 - Rising Aging Population is Driving Growth Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Phot … n made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
News – Houston Healthspan Innovation Group About Company Profile Executive Team Our Platform Client Companies JV/Partnerships Our Clients Rejenevie™ Media News Videos Covid-19 Contact Search Menu News Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development September 24, 2019 / in News / by Lee Ann Crain Houston-based accelerator to provide platform for growth to early stage life sciences and biotech companies HOUSTON, Sept. 24, 2019 /PRNewswire/ — Houston Healthspan Innovation Group is a new accelerator for early stage life sciences … and Development Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application August 21, 2019 / in News / by Lee Ann Crain New leading-edge technology produces higher yields of stem cells to enhance patient treatments HOUSTON, Aug. 21, 2019 /PRNewswire/ — Tissue Genesis, a leading developer of cell therapy processing systems, announced today that an initial group of patients was successfully treated in the first clinical application of its Icellator® X technolog … -09-12 00:31:17 Tissue Genesis’ Icellator® X Delivers Results in First Clinical Application Rejenevie™ Therapeutics Announces Start of Phase Ib Immune Restoration Treatment Clinical Trial May 29, 2019 / in News / by Lee Ann Crain Promising anti-aging stem cell therapy AR-100 shows potential in the treatment of age-related diseases HOUSTON, May 29, 2019 — Rejenevie™ Therapeutics announced the commencement of the company’s Phase Ib clinical trial to study the safety … tion Treatment Clinical Trial Dr. W.E. “Ed” Bosarge Jr. Introduces Waun Ki Hong Award Recipient at the American Association of Cancer Research’s Annual Meeting April 1, 2019 / in News / by Lee Ann Crain ATLANTA (April 1, 2019) – W.E. “Ed” Bosarge Jr., PhD gave remarks Monday, April 1 st , at the American Association of Cancer Research’s annual meeting in Atlanta. He introduced this year’s recipient of the AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research … chievement in Cancer Research , Dr. Andrew T. Chan. Bosarge endows this $10,000 award given annually to an outstanding cancer researcher under the age of 51 who has conducted highly meritorious translational and clinical cancer research. Read more https://houstonhealthspan.com/wp-content/uploads/2019/04/Bosarge-Chan-AACR-2019-800x500.jpg 500 800
Rejenevie Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Rejenevie Therapeutics Private Company | 2012 | Texas, United States | < 10 | www.rejenevie.com Private Company | 2012 | Texas, United States | < 10 | www.rejenevie.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Immune System Diseases Biological products Disease domain score A glimpse into the focused therapeutic areas No Data Technology Pl … n made by various private and public sector investors in the last five years to fund product development initiatives. Moreover, over 660 patents related to anti-aging therapeutics have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the growing aging population, ongoing pace of innovation in this field and financial support from investors, the anti-aging therapeutics market is anticipated to witness substantial growth in the mid … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
%PDF-1.5 %���� 86 0 obj > endobj xref 86 55 0000000016 00000 n 0000002123 00000 n 0000002233 00000 n 0000002267 00000 n 0000002470 00000 n 0000002697 00000 n 0000003216 00000 n 0000003638 00000 n 0000004065 00000 n 0000004167 00000 n 0000004522 00000 n 0000005458 00000 n 0000005927 00000 n 0000006456 00000 n 0000011321 00000 n 0000011718 00000 n 0000012116 00000 n 0000012442 00000 n 0000018826 00000 n 0000019294 00000 n 0000019646 00000 n 0000019924 00000 n 0000020920 00000 n 0000021980 00000 n 0000023024 00000 n 0000023446 00000 n 0000023636 00000 n 0000028344 00000 n 0000028669 00000 n 00000 … ZS endstream endobj 135 0 obj > endobj 136 0 obj >stream h�TP=��0 ��+ >stream application/postscript Dicks, Robert NCOMM_Open3.eps Adobe Illustrator CS3 2010-05-10T14:24:07+01:00 2010-10-14T13:20:02+01:00 2010-10-14T13:20:02+01:00 256 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRof … +��@A`��ָ�{�����m�+�ᵃ�h4�,3Rf�2C��ف�]�ٳ��� =zDGG �/_���kf�����_-Ƭ��~���H��RfP��,\��Y�����H��e�YfP/�2i�����t!!!��ruu%g��+++ h�=�]hjj*���_��Y�3���H�!x����y��5�2�T* � 8ˌ��z �2CA� �w�ڕ�YC�-**b�G� qqqa[�Ҵ�trr��J�rÆ L����@�)s8 �EU�m�2c� 0{m47n���������0�v��2�0�ځXfP��� `�x���� O-�������j�֭[�_�>k�,�2n�8ڑr���j�(̖@ʌ��?(�u$??�ܹsg�q�����o�o�}@a6 �A�@a6�\�����.\H���N&�K�.�����.))����T�����[/�0ˌ�l�[f�d�,eFa6�HR�"@ʌ��z �2C����!7�R��5p���� x�`HH�����+ … > endobj 81 0 obj > endobj 82 0 obj > endobj 83 0 obj > endobj 84 0 obj >stream application/pdf untitled 2011-08-15T15:35:29+08:00 Arbortext Advanced Print Publisher 9.0.225/W 2011-08-15T15:35:29+08:00 Acrobat Distiller 9.2.0 (Windows) uuid:8b199acc-c009-4c53-8187-bd146fa718c0 uuid:421ee21d-ca2b-4ad3-8c6a-bab70a3b0295 endstream endobj 85 0 obj > endobj xref 0 86 0000000000 65535 f 0000194544 00000 n 0000194687 00000 n 0000194993 00000 n 0000199563 00000 n 0000199855 00000 n 0
About Us | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu ABOUT US --> From ancient times through the folklore of Bram Stoker’s Dracula , the notion of young blood as an elixir has fascinated humankind. In 1864, French scientist Paul Bert demonstrated the concept of parabiosis , meaning living beside , by surgically connecting the circulatory systems of two mice. Bert’s explorat … ed mice exposed to the young blood supply. Rejenevie™ has developed a practical application of the parabiosis concept at the stem cell level. The goal of our immune restoration therapy is to reset the body’s immune system over about a three-month period to start producing more infection- and cancer-fighting cells and fewer inflammatory cells. We believe by boosting the immune system, we can restore a healthier life that is less laden with sickness and disease. Rejenevie™ offe
GenScript - 🔥 #GenScriptLive 𝗶𝘀 𝗖𝗼𝗺𝗶𝗻𝗴 𝘁𝗼 𝗛𝗼𝘂𝘀𝘁𝗼𝗻! An... Facebook Log In GenScript's Post GenScript Verified account October 30, 2025 · Shared with Public #GenScriptLive 𝗶𝘀 𝗖𝗼𝗺𝗶𝗻𝗴 𝘁𝗼 𝗛𝗼𝘂𝘀𝘁𝗼𝗻! An exclusive biotech networking event — drinks, connections, and real talk. 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟰, 𝟮𝟬𝟮𝟱 | 𝟱–𝟴 𝗣𝗠 𝗖𝗧 𝗦𝗼𝗰𝗶𝗮𝗹 𝗕𝗲𝗲𝗿 𝗚𝗮𝗿𝗱𝗲𝗻 (Houston) Houston’s biotech scene deserves more than rushed conference chats. That’s why we’re hosting 𝗛𝗧𝗫 𝗔𝗳𝘁𝗲𝗿 𝗛𝗼𝘂𝗿𝘀—a laid-back evening for scientists, founders, and industry leaders to: Swap i
Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Job Trends Houston Healthspan Innovation Group Launches to Transform Regenerative Medicine Research and Development September 24, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Houston Healthspan Innovation Group is a new accelerator for early stage life sciences and biotech companies focused … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Rejenevie™ Therapeutics Announces Start of Phase II Immune Restoration Treatment Clinical Trial May 29, 2019 | 4 min read Twitter LinkedIn Facebook Email Print Rejenevie™ Therapeutics announced the commencement of the company’s Phase II clinical trial to study the safety and effective … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
The Greater Houston... - Greater Houston Partnership Facebook Log In Greater Houston Partnership's Post Greater Houston Partnership Verified account 4d · Shared with Public The Greater Houston Partnership and regional allies are in San Diego for BIO International 2026! Visit Booth 4700 to learn how Houston connects early-stage biotech innovators with top research institutions, funding and a skilled workforce. Connect with us: https://ow.ly/LslZ50ZaHYF All reactions: 1 Like Comment
For Patients | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu FOR PATIENTS The goal of Rejenevie™ immune restoration therapy is to reset the aging immune system so it can produce more infection-fighting and cancer-fighting cells, and less inflammatory cells. We believe that by boosting the immune systems, we will be able to give people back a healthier lifestyle that is less lad
Home | Rejenevie Therapeutics About Us Our Mission The Science Research Overview Publications Clinical Program Overview & Safety Product Pipeline For Patients FAQs Glossary of Terms Investors & Media Company Overview In the News Video Library Contact Search Menu Revolutionizing the way we treat age-related diseases Revolutionizing the way we treat age-related diseases If aging were a disease, it would affect 100% of the human population. As we age our immune system function weakens, while systemic inflammation rises. We become more susceptible to age-related and inflammatory diseases
Heading to BIO International... - Greater Houston Partnership Facebook Log In Greater Houston Partnership's Post Greater Houston Partnership Verified account June 15 at 7:02 AM · Shared with Public Heading to BIO International 2026? Connect with our team to learn why Houston is one of the nation's leading destinations for life sciences innovation, offering access to the world's largest medical complex, a thriving innovation ecosystem and top research and industry partners. See you next week: houston.org/bio Thank you to our collaborating partners BioHouston, CenterPoint Energy ,
The Partnership's West Coast... - Greater Houston Partnership Facebook Log In Greater Houston Partnership's Post Greater Houston Partnership Verified account April 28, 2023 · Shared with Public The Partnership's West Coast delegation held productive meetings in the Bay Area to discuss Houston’s life sciences ecosystem with the California Institute for Regenerative Medicine and Bionova Scientific, while also exploring future opportunities in Houston for Google and Visa! Building on these corporate relationships will help our region attract more jobs and investment, creating a str
Exosome-mediated hematopoietic rejuvenation in a humanized mouse model indicate potential for cancer immunotherapy | bioRxiv Skip to main content Home About Submit ALERTS / RSS Search for this keyword Advanced Search New Results Exosome-mediated hematopoietic rejuvenation in a humanized mouse model indicate potential for cancer immunotherapy Steven J. Greco , Seda Ayer , Khadidiatou Guiro , Garima Sinha , Robert J. Donnelly , Markos El-Far , Sri Harika Pamarthi , Oleta A. Sandiford , Marina Gergues , Lauren S. Sherman , Michael J. Schonning , Jean-Pierre Etchegaray , Nicholas M. Ponzio , Naray … All authors edited the manuscript. Acknowledgments This work was supported by a grant from the Bosarge Family Office. Thanks to Professor Rakesh Kumar for critical input on the manuscript. Footnotes for SJG and KG, Rejenevie Therapeutics, Houston, Tx; SA, Immplacate, New York, NY References 1. ↵ Niccoli T , Partridge L . Ageing as a risk factor for disease . Curr Biol . 2012 ; 22 ( 17 ): R741 – 52 . OpenUrl CrossRef PubMed 2. ↵ Lopez-Otin C , Blasco MA , Partridge L , Serrano … 6 ): 701 – 15 . OpenUrl PubMed 61. ↵ Babicki S , Arndt D , Marcu A , Liang Y , Grant JR , Maciejewski A , et al. Heatmapper: web-enabled heat mapping for all . Nucleic Acids Res . 2016 ; 44 ( W1 ): W147 – 53 . OpenUrl CrossRef PubMed 62. ↵ Junge A , Refsgaard JC , Garde C , Pan X , Santos A , Alkan F , et al. RAIN: RNA-protein Association and Interaction Networks . Database : J Biol Databases and Curation . 2017 ; 2017 : baw167 . OpenUrl 63. ↵ Szklarczyk D , Gable AL , Lyon
After raising money through a... - Houston Business Journal Facebook Log In Houston Business Journal's Post Houston Business Journal Verified account April 26, 2023 · Shared with Public After raising money through a crowdfunding platform, the CEO of a Houston biotech company said the next step would be going public. bizjournals.com After closing crowdfunding round, Houston biotech co. FibroBiologics reconsiders IPO route All reactions: 382 5 comments 4 shares Like Comment Most relevant Pennie Raczka Big pharma doesn't want to cure anything.. It eats into their profits 3y 2 Jàmés Làçk